NASDAQ:INFI - Nasdaq - US45665G3039 - Common Stock - Currency: USD
0.0447
-0.04 (-46.98%)
The current stock price of INFI is 0.0447 USD. In the past month the price decreased by -49.26%. In the past year, price decreased by -96.66%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2000-07-27. The firm is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.
INFINITY PHARMACEUTICALS INC
1100 Massachusetts Avenue, Floor 4
Cambridge MASSACHUSETTS 02138 US
CEO: Adelene Q. Perkins
Employees: 30
Company Website: https://www.infi.com/
Phone: 16174531000.0
The current stock price of INFI is 0.0447 USD. The price decreased by -46.98% in the last trading session.
The exchange symbol of INFINITY PHARMACEUTICALS INC is INFI and it is listed on the Nasdaq exchange.
INFI stock is listed on the Nasdaq exchange.
6 analysts have analysed INFI and the average price target is 0.31 USD. This implies a price increase of 584.56% is expected in the next year compared to the current price of 0.0447. Check the INFINITY PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
INFINITY PHARMACEUTICALS INC (INFI) has a market capitalization of 4.06M USD. This makes INFI a Nano Cap stock.
INFINITY PHARMACEUTICALS INC (INFI) currently has 30 employees.
The Revenue of INFINITY PHARMACEUTICALS INC (INFI) is expected to grow by 1.89% in the next year. Check the estimates tab for more information on the INFI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
INFI does not pay a dividend.
INFINITY PHARMACEUTICALS INC (INFI) will report earnings on 2023-11-13, after the market close.
INFINITY PHARMACEUTICALS INC (INFI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.5).
ChartMill assigns a fundamental rating of 1 / 10 to INFI. INFI may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months INFI reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS increased by 5.66% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 43% to INFI. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 6.16% and a revenue growth 1.89% for INFI